TY - JOUR
T1 - Successful labeling of 99mTc-MDP using 99mTc separated from 99Mo produced by 100Mo(n,2n)99Mo
AU - Nagai, Yasuki
AU - Hatsukawa, Yuichi
AU - Kin, Tadahiro
AU - Hashimoto, Kazuyuki
AU - Motoishi, Shoji
AU - Konno, Chikara
AU - Ochiai, Kentaro
AU - Takakura, Kosuke
AU - Sato, Yuichi
AU - Kawauchi, Yukimasa
AU - Sato, Norihito
AU - Ohta, Akio
AU - Yamabayashi, Hisamichi
AU - Tanase, Masakazu
AU - Fujisaki, Saburo
AU - Teranaka, Tomoyuki
AU - Takeuchi, Nobuhiro
AU - Igarashi, Takashi
PY - 2011/8
Y1 - 2011/8
N2 - We have for the first time succeeded in separating 99mTc from a MoO3 sample irradiated with accelerator neutrons free from any radioactive impurities and in formulating 99mTc-methylene diphosphonate (99mTc-MDP). 99Mo, the mother nuclide of 99mTc, was produced by the 100Mo(n; 2n)99Mo reaction using about 14MeV neutrons provided by the 3H(d; n) 4He reaction at the Fusion Neutronics Source of Japan Atomic Energy Agency. The 99mTc was separated from 99Mo by sublimation and its radionuclide purity was confirmed to be higher than 99.99% by γ-spectroscopy. The labeling efficiency of 99mTc-MDP was shown to be higher than 99% by thin-layer chromatography. These values exceed the United States Pharmacopeia requirements for a fission product, 99Mo. Consequently, a 99mTc radiopharmaceutical preparation formed by using the mentioned 99Mo can be a promising substitute for the fission product 99Mo, which is currently produced using a highly enriched uranium target in aging research reactors. A longstanding problem to ensure a reliable and constant supply of 99Mo in Japan can be partially mitigated.
AB - We have for the first time succeeded in separating 99mTc from a MoO3 sample irradiated with accelerator neutrons free from any radioactive impurities and in formulating 99mTc-methylene diphosphonate (99mTc-MDP). 99Mo, the mother nuclide of 99mTc, was produced by the 100Mo(n; 2n)99Mo reaction using about 14MeV neutrons provided by the 3H(d; n) 4He reaction at the Fusion Neutronics Source of Japan Atomic Energy Agency. The 99mTc was separated from 99Mo by sublimation and its radionuclide purity was confirmed to be higher than 99.99% by γ-spectroscopy. The labeling efficiency of 99mTc-MDP was shown to be higher than 99% by thin-layer chromatography. These values exceed the United States Pharmacopeia requirements for a fission product, 99Mo. Consequently, a 99mTc radiopharmaceutical preparation formed by using the mentioned 99Mo can be a promising substitute for the fission product 99Mo, which is currently produced using a highly enriched uranium target in aging research reactors. A longstanding problem to ensure a reliable and constant supply of 99Mo in Japan can be partially mitigated.
UR - http://www.scopus.com/inward/record.url?scp=80051594081&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051594081&partnerID=8YFLogxK
U2 - 10.1143/JPSJ.80.083201
DO - 10.1143/JPSJ.80.083201
M3 - Article
AN - SCOPUS:80051594081
SN - 0031-9015
VL - 80
JO - Journal of the Physical Society of Japan
JF - Journal of the Physical Society of Japan
IS - 8
M1 - 083201
ER -